3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Breast Neoplasms
449
Carcinoma, Non-Small-Cell Lung
372
Neoplasms
349
Prostatic Neoplasms
285
Colorectal Neoplasms
273
Multiple Myeloma
211
Lung Neoplasms
201
Neoplasm Metastasis
185
Leukemia, Myeloid, Acute
163
Ovarian Neoplasms
159
Pancreatic Neoplasms
155
Squamous Cell Carcinoma of Head and Neck
140
Melanoma
131
Recurrence
108
Glioblastoma
105
Head and Neck Neoplasms
103
Carcinoma, Renal Cell
103
Endometrial Neoplasms
100
Precursor Cell Lymphoblastic Leukemia-Lymphoma
97
Lymphoma, Non-Hodgkin
95
Stomach Neoplasms
94
Carcinoma, Hepatocellular
94
Lymphoma
93
Triple Negative Breast Neoplasms
92
Brain Neoplasms
90
Uterine Cervical Neoplasms
86
Lymphoma, Large B-Cell, Diffuse
81
Glioma
79
Urinary Bladder Neoplasms
78
Sarcoma
78
Interventions
4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Amyloid Neuropathies, Familial
×
30 days
×
Clear all
NCT05184088
2026-06-02
CArdiag
Lantheus Biosciences Ltd.
Phase 3
Completed
244 enrolled